LobbyingBiosplice Therapeutics lobbying by quarter
Biosplice Therapeutics's latest lobbying report covers Q2 2026, at $110K. The four quarters Q4 2025–Q3 2026 total $240K. Its first report covers Q4 2025; the issues it reports most are Health Issues.
Biosplice Therapeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $240K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $60K | 1 |
| Q1 2026 | $70K | 1 |
| Q2 2026 | $110K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$240K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
- Food & Drug Administration (FDA)2 reports
- Health & Human Services, Dept of (HHS)2 reports
- Executive Office of the President (EOP)1 reports
- Office of Management & Budget (OMB)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Akin Gump Strauss Hauer & Feld | $240K | 3 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MOLLY BRIMMER-LOLLI | Sr Cnsl, H Energy&Commrce Comm, Health Subcomm (2025-26); Cnsl H Energy&Commrce Comm, Health Subcomm (2023-25); Leg Dir, Rep. Hudson (2022-23); Sr Health Policy Advsr Rep. Hudson (2021-22); Leg Asst, Rep. Harris (2019-2021); Intrn, Rep. Harris (2014) | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Akin Gump Strauss Hauer & Feld | $110K |
| 04/20for Q1 | Akin Gump Strauss Hauer & Feld | $70K |
| 01/20for Q4 2025 | Akin Gump Strauss Hauer & Feld | $60K |
| 25/10/27for Q4 2025 | Akin Gump Strauss Hauer & Feld | Under $5,000 |